Partial loss of TANK-binding kinase 1 (TBK1) causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Xu et al. identify the role of TBK1 in suppressing neuroinflammation and apoptosis by its inhibition of the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and elucidate how aging and genetic susceptibility together cause neuroinflammation.
Partial loss of TANK-binding kinase 1 (TBK1) causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Xu et al. identify the role of TBK1 in suppressing neuroinflammation and apoptosis by its inhibition of the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and elucidate how aging and genetic susceptibility together cause neuroinflammation.
A recent milestone discovery in neurodegeneration was that heterozygous lossof-function mutations in the gene encoding TANK-binding kinase 1 (TBK1) cause instances of both familial and sporadic ALS and the second-most frequently occurring dementia, frontotemporal dementia (FTD) . Although these two diseases have highly divergent phenotypic presentations-ALS is a fatal disease of progressive paralysis driven by degeneration of motor neurons, whereas FTD is a dementia characterized by personality changes accompanied by atrophy of the frontal cortex-they share common pathological features and genetic causes (Cirulli et al., 2015; Freischmidt et al., 2015; Taylor et al., 2016) . Some TBK1 mutant alleles produce no functional kinase from premature translation terminators coupled with nonsense mediated decay of the mRNA. Others encode proteins containing point mutations that probably reduce overall kinase activity or reduce TBK1 binding to adaptor proteins that mediate intracellular localization. Thus, TBK1 haploinsufficiency undeniably causes ALS and FTD, but the underlying molecular mechanism(s) had previously not been determined. In this issue of Cell, Xu et al. (2018) provide strong genetic and molecular evidence that TBK1 suppresses (1) apoptosis during development and (2) an inflammatory response in the aged brain, and it does both of these by its inhibitory phosphorylation of another kinase, the receptor-interacting serine/threonine-protein kinase 1 (RIPK1).
Initially identified in 1999 by David Baltimore's group, TBK1 is widely known as an essential component for both the type I interferon response and autophagy (Ahmad et al., 2016) . During the antiviral innate immune response, viral DNA or RNA activates TBK1, which phosphorylates the downstream transcription factors IRF3 and IRF7. Phosphorylated IRF3 and IRF7 dimerize, translocate into the nucleus, and initiate the transcription of type I interferons. TBK1 also promotes autophagy. TBK1 phosphorylates autophagy receptors, increasing their binding affinity to ubiquitin chains that mark cargos for delivery to autophagosomes, including damaged mitochondria, ubiquitin-coated intracellular bacteria, and ubiquitinated proteins. However, neither of these known activities explains the lethality of TBK1 null mouse embryos, which die at E13.5 from massive apoptosis in liver. Remarkably, this runaway apoptosis is rescued by deleting the tumor necrosis factor receptor 1 (TNFR1) or its ligand, TNFa, initially implicating TBK1 as a suppressor of TNFainduced apoptosis (Perry et al., 2004) . Xu et al. (2018) now establish the essential role of TBK1 in repressing RIPK1-dependent apoptosis and inflammation downstream of TNFR1. They first determine that TNFa induces apoptosis in Tbk1
, but not wild-type fetal liver and murine embryonic fibroblasts (MEFs). Mechanistically, RIPK1 is demonstrated to be hyperactive in the absence of TBK1. Remarkably, conversion of one or both RIPK1 alleles to ones that encode a kinase inactive point mutation fully restores viability of Tbk1 À/À mice.
Prior work had established that RIPK1 controls two types of programmed cell death: RIPK1-dependent apoptosis and necroptosis, the latter a cell death process that uses kinases rather than activated caspases to drive programmed death, ultimately targeting MLKL, an executer pseudokinase that may drive cell lysis by recruitment of Ca 2+ or Na + ion channels or as a direct pore-forming complex. Another death-related kinase, RIPK3, potentiates RIPK1-induced necroptosis by phosphorylating and activating MLKL (Wallach et al., 2016) . To that, Xu et al. (2018) now identify that complete loss of RIPK3 can rescue the lethality of Tbk1 À/À (admittedly, it does so only in a minority of mice). Loss or inhibition of TBK1 is further shown to sensitize cells to apoptosis in vitro and in vivo, pinpointing that TBK1 is a suppressor of RIPK1-dependent apoptosis. Interestingly, RIPK1-independent apoptosis (modeled by TNFa addition coupled with suppression of protein synthesis with cycloheximide) can be converted to RIPK1-dependent apoptosis by depleting TBK1. In response to TNFa, Tbk1 null embryos and MEFs also express a higher load of proinflammatory cytokines, an effect abolished by inhibiting RIPK1. Next, Xu et al. (2018) identify the molecular interactions between TBK1 and RIPK1 that underlie a classic example of epistasis ( Figure 1A )-i.e., the interaction of two (or more) genes, which in this case represents the typical epistatic example in which one gene (TBK1) suppresses another (RIPK1). The TNFR1 signaling complex (TNF-RSC) is shown to recruit and activate TBK1 after binding to TNFa, a process largely blocked by depletion of RIPK1. Ubiquitinated RIPK1 is required for the recruitment of TBK1.
Deletion of Hoip, the E3 ubiquitin-protein ligase of the linear ubiquitin assembly complex (LUBAC), completely abolishes TBK1 translocation to the TNF-RSC. The direct recruitment of TBK1 by ubiquitinated RIPK1 raised the possibility that TBK1 may phosphorylate and inhibit RIPK1. Using mass spectrometry, Xu et al. (2018) identify a conserved threonine residue (T189) in the human RIPK1 kinase domain as a direct substrate of TBK1. T189 is critical for substrate recognition by RIPK1. Phosphorylation of T189 blocks substrate recognition and suppresses the kinase activity of RIPK1, whose activation loop requires transphosphorylation to stabilize the active kinase conformation ( Figure 1A) . Xu et al. (2018) determine that Tbk1 null MEFs hyperactivate TAK1, another kinase whose activity inhibits RIPK1 ( Figure 1A) . Starting from the hypothesis that overactivation of TAK1 might compensate for haploinsufficiency of TBK1, they identify that during normal aging, there is an attenuation of the protein expression of TAK1 in the human brain. Thus, increased TAK1 activity early in life may compensate for reduced TBK1 activity, but this beneficial effect will be diminished in aged brains, providing an explanation for age dependency in ALS and FTD caused by mutations that reduce TBK1 activity. Consistent with this hypothesis, MEFs heterozygous for Tbk1 and Tak1 expression are sensitive to TNFa-induced apoptosis.
The effects of an age-dependent decrease of TAK1 in microglia were directly tested in mice by combining Tbk1 +/À with a myeloid cell-specific Tak1 hypomorph (Tak1 DM/+ ). Tak1 reduction in microglia caused increased anxiety, an FTD-like behavior, increased microgliosis, axonal degeneration, increased neuronal apoptosis, decreased number of cortical neurons, and cytosolic ; Ripk1 D138N/+ triply heterozygous mice, which combined partial inhibition of RIPK1 with systemic reduction in TBK1 and myeloid reduction in TAK1. Thus, microglia-specific overactivation of RIPK1 produces a non-autonomous toxicity to the neurons ( Figure 1B) .
Unresolved is why some cells execute RIPK1-dependent apoptosis and others stimulate inflammation downstream of a common TNFa stimulus. For example, in TBK1-or TAK1-deficient backgrounds, TNFa triggers death in MEFs and hepatocytes but promotes proliferation and cytokine secretion in myeloid cells. It should be emphasized that beyond myeloid cells, TBK1 is also expressed in neurons, astrocytes, and oligodendrocytes, so it will now be of high interest to determine whether reducing TBK1 causes any susceptibility in aging neurons or glia.
About 70% of familial and 10% of sporadic ALS cases can be explained by dominant mutation in a single gene, most of which are gain of toxicity (Taylor et al., 2016) . Added to this are disease examples caused by hypomorphic genetic deficits (TBK1 is the best example). Penetrance of most of these mutations is incomplete (i.e., not all mutation carriers develop disease), implicating a combination of oligogenic or environmental contributors to pathogenesis. This is certainly true for mutations in TBK1 (Freischmidt et al., 2015) .
Regarding therapy development, consideration of all of the current evidence supports an approach of selectively inhibiting RIPK1 activity as a plausible therapy for ALS and FTD (Ito et al., 2016; Xu et al., 2018) . While complete loss of RIPK1 protein (and activity) causes severe immunodeficiency and inflammatory bowel disease in man (Cuchet-Lourenç o et al., 2018) and early lethality in mice, mice expressing RIPK1 mutants that have no kinase activity are remarkably normal (implicating a yet unidentified role for the RIPK1 protein beyond its kinase activity). Encouragingly, RIPK1 inhibitors have been shown to be safe in two clinical trials. An additional potential therapeutic approach might be to inhibit RIPK1 selectively within the nervous system by use of antisense oligo nucleotides (Smith et al., 2006) to reduce (but not eliminate) RIPK1 protein levels by catalyzing RIPK1 mRNA degradation. Of course, targeting neuroinflammation as a therapy is predicated on the hypothesis that suppressing neuroinflammation after disease onset is not too late to slow disease advance. Let's hope that proves true.
